Vasotocin derivatives
    1.
    发明授权
    Vasotocin derivatives 失效
    血管生成衍生物

    公开(公告)号:US4504469A

    公开(公告)日:1985-03-12

    申请号:US561920

    申请日:1983-12-15

    CPC分类号: C07K7/16 A61K38/00 Y10S930/15

    摘要: Novel vasotocin derivatives having an inhibitory effect on uterine contractions, pharmaceutical compositions containing these derivatives, and the use thereof in the therapeutical treatment of excessive muscle contractions in the uterus and described. The derivatives differ from vasotocin in that the structure of the original hormone has been modified at positions 1, 2 and, optionally, 4 and/or 8. The vasotocin derivatives thus have the formula ##STR1## wherein Mpa is a 3-mercaptopropionoyl residue (--S--CH.sub.2 --CH.sub.2 --CO--);A is the peptide residue of L- or D-tyrosine-O-ethyl ether (in other words, 4-ethoxy-L or D-phenyl alanine, i.e. L- or D-Tyr(Et)), or of a hydrophobic D-amino acid, such as D-tyrosine(D-Tyr) or D-tryptophane(D-Trp);Ile is the peptide residue of isoleucine;B is the peptide residue of glutamine (Gln), treonine (Thr) or valine (Val);Asn is the peptide residue of asparagin;Cys is the peptide residue of cysteine;Pro is the peptide residue of proline;C is the peptide residue of L- or D-arginine (Arg), ornithine (Orn) or citrullin (Cit); andGly--NH.sub.2 is the peptide residue of glycine amide.

    摘要翻译: 具有对子宫收缩的抑制作用的新型血管生成物衍生物,含有这些衍生物的药物组合物及其在治疗性治疗子宫中过度肌肉收缩的用途及其用途。 衍生物不同于血管生成素,因为原始激素的结构已经在1,2和任选的4和/或8位被修饰。因此,血管生成物衍生物具有式“IMAGE”,其中Mpa是3-巯基丙酰基残基( -S-CH 2 -CH 2 -CO-); A是L-或D-酪氨酸-O-乙基醚的肽残基(换句话说,4-乙氧基-L或D-苯基丙氨酸,即L-或D-Tyr(Et))或疏水性D - 氨基酸,如D-酪氨酸(D-Tyr)或D-色氨酸(D-Trp); Ile是异亮氨酸的肽残基; B是谷氨酰胺(Gln),枸橼酸(Thr)或缬氨酸(Val)的肽残基; Asn是天冬酰胺的肽残基; Cys是半胱氨酸的肽残基; Pro是脯氨酸的肽残基; C是L-或D-精氨酸(Arg),鸟氨酸(Orn)或瓜氨酸(Cit)的肽残基; Gly-NH2是甘氨酰胺的肽残基。

    Oxytocin derivatives
    2.
    发明授权
    Oxytocin derivatives 失效
    催产素衍生物

    公开(公告)号:US4402942A

    公开(公告)日:1983-09-06

    申请号:US238715

    申请日:1981-02-27

    申请人: Per O. R. Melin

    发明人: Per O. R. Melin

    摘要: New oxytocin derivatives having an inhibitory effect on uterine contractions, pharmaceutical compositions containing the oxytocin derivatives, and use of the derivatives in the production of medicines are described. The derivatives are 1-deamino-(2-O-alkyltyrosine)-oxytocin of the formula ##STR1## wherein Mpa is a 3-mercaptopropionyl residue and X is an alkyl group having 2-4 carbon atoms, preferably an ethyl group. Apart from their inhibitory effect on vasopressin and oxytocin induced uterine contractions, the new oxytocin derivatives are capable of inhibiting the spontaneous contraction pattern of the uterus.

    摘要翻译: 描述了对子宫收缩具有抑制作用的新催产素衍生物,含有催产素衍生物的药物组合物及其衍生物在制备药物中的应用。 所述衍生物是式“IMAGE”的1-脱氨基 - (2-O-烷基酪氨酸) - 催产素,其中Mpa是3-巯基丙酰基残基,X是具有2-4个碳原子的烷基,优选乙基。 除了它们对加压素和催产素诱导的子宫收缩的抑制作用外,新的催产素衍生物能够抑制子宫的自发收缩模式。